中国骨质疏松杂志

注射甲状旁腺素相关肽6个月后停药18个月骨密度随访

Bone mineral density in postmenopausal osteoporosis after PTHrP 1-34 injection for 6 months then followed up for 18 months

DOI：10.3969/j.issn.1006-7108.2019.02.022

中文关键词: 甲状旁腺素相关肽绝经后骨质疏松骨密度

英文关键词:rPTH postmenopausal osteoporosis bone mineral density

基金项目:

作者	单位
刘洁* 晁爱军曹虹王莉	天津医院骨内科，天津 300211

摘要点击次数: 1082

全文下载次数: 443

中文摘要:

目的研究重组人甲状旁腺素相关肽注射6个月治疗绝经后骨质疏松，随后停药18个月时，对于骨密度是否仍存在作用。方法以采用甲状旁腺素相关肽注射6个月的32例绝经后骨质疏松患者作为研究对象，同时选取年龄匹配的绝经后骨质疏松患者26例作为对照组。比较治疗组和对照组在治疗6个月及停药18个月时的骨密度变化。结果 6个月后治疗组腰椎骨密度平均增加(1.115±3.711)%，全髋骨密度下降(0.498±2.871)%，股骨颈骨密度增加(0.127±4.912)%；对照组在腰椎下降(1.773±2.626)%，全髋下降(1.255±3.02)%，股骨颈增加(1.959±4.065)%；除腰椎外，两组比较差异均无统计学意义(P＞0.05)；停止治疗18个月时，治疗组腰椎骨密度增加(2.210±8.171)%，全髋下降(0.734±4.266)%，股骨颈下降(1.854±4.184)%；对照组腰椎下降(2.004±5.065)%，全髋下降(3.271±3.003)%，与治疗组比较差异有统计学意义(P＜0.05)，股骨颈下降(2.704±2.659)%，与治疗组比较差异无统计学意义(P＞0.05)。两组人群均未出现严重的不良反应。结论对于绝经后骨质疏松妇女应用甲状旁腺相关肽6个月，随后停药18个月时，对腰椎和全髋骨密度仍有一定的保护作用。

英文摘要:

Objective To investigate if there is continuous effect on bone mineral density (BMD) in postmenopausal osteoporosis in Chinese women who received an injection of parathyroid hormone related protein (PTHrP ) 1-34 for 6 months and then stopped and followed up for 18 months (24 months from baseline). Methods Thirty-two Chinese postmenopausal osteoporosis women who met the inclusion criteria and without the exclusion conditions were investigated as treatment group, they were all treated with PTHrP 1-34 20μg, Alfacalcidol 0.5μg and 600 mg elementary calcium daily. Another twenty-six patients with matched age and gender served as controls, they received Alfacalcidol 0.5μg and elementary calcium 600 mg daily only. All drugs were given for 6 months and then discontinued for 18 months. BMD changes were compared between the treatment group and the control group at 6 months after treatment and 18 months after drug withdrawal. Results 6 months after receiving PTH treatment, the changes of BMD were 1.115±3.711% at the lumbar spine, - 0.498±2.871% at total hip and 0.127±4.912% at neck of femur in the treatment group; in contrast in the control group the changes were -1.773±2.626% at lumbar spine, -1.255±3.02% at total hip and 1.959±4.065% at neck of femur (P<0.05 for lumbar spine, and P>0.05 for hip and femoral neck comparing between the two group). At 18 months after PTH treatment completed, in the treatment group BMD increased by 2.210±8.171% at lumbar spine, decreased by 0.734±4.266% at total hip and decreased by 1.854±4.184% at femur neck compared with baseline; in the control group, BMD decreased by 2.004±5.065% at lumbar spine, by 3.271±3.003% at total hip and by 2.704±2.659% at femur neck (P<0.05 for lumbar spine and total hip, and P>0.05 for femoral neck comparing between the two groups). About 68.75% (22/32) vs 19.24% (5/26) (P<0.05) at lumbar spine, 56.25% (18/32) vs 15.38%(4/26) (P<0.05) at total hip and 37.5% (12/32) vs 19.24%(5/26) (P>0.05) at femur neck whose BMD was higher than baseline in treatment group compared with controls after completing rPTH 1-34 injection for 18 months. There were no serious adverse reactions during the study. Conclusion After injection of PTH for 6 months, the benefit on BMD of lumbar spine and total hip could last for 18 months, it shows that injection of rPTH1-34 for 6 months is an effective method in the treatment of osteoporosis in Chinese postmenopausal women.

查看全文查看/发表评论下载PDF阅读器

关闭